Notícias

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.

Moderna Inc. (NASDAQ:MRNA) saw its share price more than double week-on-week to hit a new record high after reporting stellar results from the clinical trial of its melanoma therapy candidate in partnership with Merck. During the week, the stock climbed by as much as 179 percent to touch a record high of $176.66, before paring […]

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.

Plus, the secret’s out on the Catskills, and Democrats gear up for a wave of investigations into Trump and his allies.

Check out the companies making headlines this week:

ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.

Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel."

The stock has gained over 20% in the past five days, marking its best week since early July.

The Standard & Poor's 500 index fell 1.4% this week, its first weekly loss in a month, as US Preside

The stock market still looks basically healthy, but the bond market is starting to show signs of stress.

It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher. Moderna stock saw its best weekly performance ever, rising over 140%. The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

*US equity indexes were lower this week after President Donald Trump warned of severe economic sanct

Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

The S&P 500 Index ($SPX ) (SPY ) is up by +0.38% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.09%. E-mini S&P futures (ESU26 ) are up +0.37%, and September E-mini...

Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.

The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday. Friday’s swing is happening while the broader market barely moves, with the S&P 500 up 0.3% and the NASDAQ 100 up 0.1%. That backdrop shows the volatility ... Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

JPMorgan layoffs hit highest since 2015, Amazon expands drone delivery, Chinese tech IPOs outshine U.S. rivals, and more news to start your day.

The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.

Moderna shares rise to close out a week of wild swings, while crypto stocks extend their recent rally.

Former hedge fund manager Martin Shkreli revealed he was shorting Moderna Inc. at $80 per share just weeks before the biotech stock experienced a record-breaking 177% explosion on Thursday. Deconstructing the unexpected rally, the “Pharma Bro” admitted Wall Street was...

Moderna stole the show this week, but healthcare has been breaking out for months

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a...

↗️ Strategy (MSTR), Coinbase (COIN), American Bitcoin (ABTC): Shares in the crypto-related companies continued their climb premarket after President Trump met with digital currency leaders earlier this week.

The Morning Bull - US Market Morning Update Friday, Aug, 21 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts edging down about 0.1%, as investors digest a fresh mix of interest rate and bond market signals. The US Treasury plans to double its buybacks of long term bonds, which has pulled 30 year yields lower and is an attempt to ease the pressure from higher borrowing costs. At the same time, Federal Reserve minutes show some officials were ready to raise...